Deferred Income Tax Expense (Benefit) in USD of Anika Therapeutics, Inc. from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Anika Therapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2010 to Q1 2025.
  • Anika Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2025 was $18K, a 90.7% decline year-over-year.
  • Anika Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was $260K.
  • Anika Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$6.33M, a 20.1% decline from 2022.
  • Anika Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$5.27M, a 198% decline from 2021.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)

Anika Therapeutics, Inc. Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $18K -$175K -90.7% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-09
Q1 2024 $193K +$2.57M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-09
Q1 2023 -$2.37M -$2.1M -769% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2022 -$273K +$889K +76.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q1 2021 -$1.16M -$1.71M -311% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q1 2020 $550K +$674K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q1 2019 -$124K -$49K -65.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-22
Q1 2018 -$75K -$460K -119% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-06
Q1 2017 $385K -$170K -30.6% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q1 2016 $555K +$732K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
Q1 2015 -$177K +$147K +45.3% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-03
Q1 2014 -$324K -$184K -132% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-04
Q1 2013 -$140K -$57.5K -70% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-05
Q1 2012 -$82.2K +$29.1K +26.1% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-06
Q1 2011 -$111K Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-07

Anika Therapeutics, Inc. Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $260K +$6.59M Jan 1, 2024 Dec 31, 2024 10-K 2025-03-17
2023 -$6.33M -$1.06M -20.1% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-17
2022 -$5.27M -$3.5M -198% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-17
2021 -$1.77M +$1.78M +50.2% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-15
2020 -$3.54M -$4.34M -546% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-16
2019 $794K +$2.61M Jan 1, 2019 Dec 31, 2019 10-K 2022-03-11
2018 -$1.82M -$619K -51.7% Jan 1, 2018 Dec 31, 2018 10-K/A 2021-04-26
2017 -$1.2M -$1.13M -1743% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-06
2016 -$65K +$682K +91.3% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-27
2015 -$747K -$1.56M -192% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-27
2014 $815K -$1.39M -63.1% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-24
2013 $2.21M +$2.22M Jan 1, 2013 Dec 31, 2013 10-K 2016-03-10
2012 -$10.3K -$2M -101% Jan 1, 2012 Dec 31, 2012 10-K 2015-03-13
2011 $1.99M +$35.8K +1.83% Jan 1, 2011 Dec 31, 2011 10-K 2014-03-13
2010 $1.95M Jan 1, 2010 Dec 31, 2010 10-K 2013-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.